Indivior Pharmaceuticals Inc

2 months ago · zacks.com

Indivior announces a merger with Supernus to form a CNS-focused biopharma company, tops Q2 earnings and revenue estimates and raises its 2026 outlook.

2 months ago · prnewswire.com

NEW YORK, Aug. 3, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Indivior Pharmaceuticals, Inc. (NASDAQ: INDV ) related to its merger with Supernus Pharmaceuticals, Inc. Upon closing of the proposed transaction, Indivior shareholders will own approximately 56.5% of the combined company.

3 months ago · zacks.com

Sublocade is powering Indivior's growth with record patient starts, rising volumes and a stable market share, setting up key demand tests for 2026.

4 months ago · zacks.com

INDV, RNW, LCUT, NTCT and TNK passed a screen for efficiency, outperforming industry peers on inventory, receivables, assets and margins.

4 months ago · globenewswire.com

RICHMOND, Va., May 20, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc., (Nasdaq: INDV) today announced findings from two new real-world evidence studies showing that adherence to extended-release buprenorphine, a monthly injectable commercially available as SUBLOCADE®, is associated with lower relapse risk, fewer infection-related complications, and reduced healthcare utilization among people living with opioid use disorder (OUD). “Collectively, these studies highlight the benefits of sustained treatment with monthly injectable buprenorphine, including reduced relapse risk and fewer serious complications that often drive acute care use,” said Christian Heidbreder, Ph.D., Chief Scientific Officer at Indivior. “These findings also emphasize the importance of proactively identifying patients at risk of treatment discontinuation and supporting continued access to evidence‑based medications for opioid use disorder.”

5 months ago · globenewswire.com

RICHMOND, Va., April 16, 2026 (GLOBE NEWSWIRE) -- Indivior PLC (Nasdaq: INDV) today announced results from a national survey published in the Journal of Correctional Health Care showing that correctional leaders identify staffing and coordination gaps as key barriers to reducing diversion of medications for opioid use disorder (MOUD) and recognized long-acting injectable (LAI) buprenorphine as a strategy to help mitigate diversion and improve treatment in jail and prison settings.

6 months ago · globenewswire.com

Model estimates SUBLOCADE® may reduce staff time and associated costs compared with other medications for opioid use disorder in jails and prisons RICHMOND, Va., March 31, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc., (Nasdaq: INDV) today announced findings from a new cost impact model published in The Journal of Current Medical Research and Opinion, estimating that the use of extended-release buprenorphine, a monthly injectable commercially available as SUBLOCADE®, may reduce staff time and associated costs in jails and prisons compared with other medications for opioid use disorder (MOUD).

6 months ago · globenewswire.com

Patients adherent to SUBLOCADE ® for 12 months had 42% lower adjusted non-MOUD medical costs vs. those adherent to other forms of MOUD Patients adherent to SUBLOCADE had the lowest inpatient, emergency department, and detoxification utilization across all treatment groups RICHMOND, Va.